Amol V. Tendolkar, Clinical Pharmacology & Pharmacometrics

Director
Bristol Myers Squibb

Poster(s):

• (T-118) Population Pharmacokinetic and Exposure-Response Analyses of Neoadjuvant Nivolumab plus Chemotherapy, followed by Adjuvant Treatment with Nivolumab in Subjects with Resectable Stage II-IIIB NSCLC
  Tuesday, November 12, 2024

  7:00 AM – 5:00 PM MST